Verastem, Inc. — 2015 Form 10-K Summary
Business context and reporting period
Verastem is a clinical-stage biopharmaceutical company developing oncology therapies targeting cancer stem cells, tumor immunity and the tumor microenvironment. Its lead candidates were VS-6063 (defactinib), VS-4718 and VS-5584, targeting FAK and PI3K/mTOR pathways. The filing covers the fiscal year ended December 31, 2015; fourth-quarter figures are unaudited.
Financial results and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue generated |
| Research and development expense | $40.6 million | $35.4 million | Up $5.2 million |
| General and administrative expense | $17.6 million | $18.2 million | Down $0.5 million |
| Total operating expenses | $58.2 million | $53.6 million | Up $4.6 million |
| Net loss | $57.9 million | $53.4 million | Loss increased $4.5 million |
| Net loss per share | $1.61 | $2.07 | Loss per share improved due primarily to share issuance |
| Cash used in operating activities | $45.6 million | $36.9 million | Use increased $8.7 million |
| Cash, cash equivalents and investments | $110.3 million | $92.7 million | Up $17.6 million |
Fourth-quarter 2015 operating expenses were $12.0 million and net loss was $11.9 million, or $0.32 per share, compared with fourth-quarter 2014 operating expenses of $14.0 million and net loss of $13.9 million, or $0.53 per share.
Gross and operating margins are not meaningful because the company had no revenue. The company reported no funded debt in the disclosed balance sheet; total liabilities were $10.6 million, primarily accounts payable, accrued expenses and other liabilities. Working capital was $100.7 million at year-end.
Financing activities generated $63.6 million in 2015, principally from a January follow-on offering and at-the-market sales. The company sold 8.34 million shares in the follow-on offering for $50.9 million of net proceeds and 1.19 million shares through its at-the-market program for approximately $10.9 million of net proceeds.
Material changes versus the prior comparable period
- R&D expense increased 15%, driven primarily by higher contract research organization, clinical and development services, personnel and consulting costs.
- VS-6063-related external program spending increased to $20.7 million from $16.2 million; VS-5584 spending was $2.7 million and VS-4718 spending was $2.5 million.
- Cash used in operations increased as clinical development activity expanded, while year-end liquidity increased because of equity financing.
- In October 2015, the company reduced its workforce by approximately 50%, to approximately 20 full-time employees. Expected annual cash savings were approximately $5.1 million, with estimated one-time severance and related costs of $1.1 million, of which $713,000 was expected to be paid in 2016.
- Accumulated deficit increased to $198.9 million from $141.0 million.
- Stock-based compensation remained material at approximately $9.7 million, and approximately $10.0 million of unrecognized option expense remained at year-end.
Clinical outlook, commentary and risks
- The company expected existing cash, cash equivalents and investments to fund its current operating plan and capital expenditure requirements into 2018, although this estimate depended on assumptions that could prove incorrect.
- Management expected continuing operating losses and substantial additional funding needs. No committed external funding source existed, and future financing could dilute shareholders or require the company to relinquish rights.
- Enrollment in the Phase 2 COMMAND study of VS-6063 in mesothelioma was stopped in September 2015 for futility after an interim analysis found insufficient efficacy. This materially weakened the near-term development and commercialization outlook for VS-6063.
- Other VS-6063 programs remained active, including studies in ovarian cancer, non-small cell lung cancer, pancreatic cancer and mesothelioma. The company expected a pancreatic cancer combination-study data readout in 2017 and additional combination trials in 2016.
- VS-4718 remained in Phase 1 studies, including combination treatment with gemcitabine and nab-paclitaxel; VS-5584 remained in Phase 1 development, including expansion cohorts planned for 2016.
- All candidates remained unapproved and dependent on successful clinical trials, regulatory approval, manufacturing scale-up and market acceptance. The filing states that product revenue may not occur for several years, if ever.
- Key risks included clinical failure, adverse events, patient enrollment delays, regulatory rejection, reliance on contract research organizations and manufacturers, limited manufacturing redundancy, intellectual-property challenges, competition and uncertain reimbursement.
- Orphan drug designations had been granted for VS-6063 in ovarian cancer and mesothelioma in the United States, European Union and Australia; designation did not guarantee approval or commercial success.
- The company reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2015. The filing reported no unresolved staff comments, legal proceedings or off-balance-sheet arrangements.
Most important facts to verify
- Confirm the detailed 2015 audited financial statements, particularly cash burn, investment composition, accrued clinical costs and the absence of funded debt.
- Reconcile the cash-runway statement through 2018 with the $45.6 million annual operating cash burn, planned trials and expected financing requirements.
- Assess the implications of COMMAND futility for VS-6063 and whether subsequent combination-trial data support continued development.
- Review dilution risk from outstanding options, warrants and future equity financing; 5.39 million options and 142,857 warrants were outstanding at year-end.
- Verify contractual license obligations, including potential milestones, royalties and annual maintenance fees to Pfizer, Whitehead, Scripps and S*Bio.
- Monitor restructuring execution, remaining severance payments and whether the projected $5.1 million annual savings are realized.
- Evaluate clinical safety, enrollment, regulatory status and data quality because several reported results were preliminary or based on unaudited investigator data.